Where drug discovery can take you

Pharmaceutical companies are increasingly integrating artificial intelligence and automation into the design, make, test, and analyze (DMTA) cycle to accelerate drug discovery, according to industry leaders at TTP plc. Wenshu Xu and Jon Wingfield note that while AI investment is substantial, improving decision-making speed alone is insufficient without connecting the make and test stages. The next-generation DMTA approach aims to overcome the traditional cycle's slow iteration speed, positioning companies for higher productivity in preclinical drug development.